

## **SABINSA NEWS RELEASE**

### **RESEARCH PUBLISHED ON SABINSA'S CURCUMIN C3 COMPLEX® / BIOPERINE® COMBINATION AS ADJUVANT THERAPY IN COVID-19 PATIENTS**

**East Windsor, NJ (June 24, 2021)** - Sabinsa's flagship combination product, Curcumin C3 Complex® with BioPerine® (525mg/2.5 mg twice a day, 14 days), was used as adjuvant therapy for COVID-19 in a double-blind, randomized controlled clinical trial conducted on COVID-19 patients in India, where the wide-spread virus infection has strained the healthcare system.

The trial involved a total of 140 patients with mild, moderate, and severe symptoms of COVID-19 in a hospital exclusively for COVID-19 patients. While mild/moderately symptomatic patients were admitted to the wards, patients with severe symptoms were in the hospital's intensive-care unit. The treatment outcome was gauged by the pre-defined primary and secondary outcome measures.

Patients in the group who received the C3 Complex + BioPerine adjuvant treatment showed quicker symptomatic recovery (of fever, cough, sore throat, breathlessness), had a lower incidence of red-flag signs, and better ability to maintain oxygen saturation >94% on room air only. The D-dimer levels were less severe in C3-group than in the non-C3-group. While some patients in the moderate non-C3 group needed Tocilizumab injections, none in the corresponding moderate C3-group required such intervention. Fewer in the C3-group needed mechanical ventilator support or suffered thromboembolic episodes than in the non-C3 group.

Further details can be found in the paper published in **Frontiers in Pharmacology** which concluded that oral curcuminoids/piperine combination as adjuvant therapy in COVID-19 treatment could reduce morbidity and mortality and ease the logistical and supply-related burdens on the healthcare system. The authors further stated that this was the first study on curcuminoids/piperine combination on COVID-19 patients.

"While larger trials will be needed to establish the findings of the study on a firmer footing, it is gratifying to learn of these promising preliminary results," said Dr. Muhammed Majeed, Founder and Chairman of Sami-Sabinsa group.

To access the study: <https://doi.org/10.3389/fphar.2021.669362>

#### **About Sabinsa**

Sabinsa, founded in 1988, is a manufacturer and supplier of herbal extracts, cosmeceuticals, probiotics, minerals, and specialty fine chemicals. The company markets over 100 standardized botanical extracts and employs more than 1000 people worldwide in 12 manufacturing, R&D, sales, and distribution facilities. Process development and product innovation form the focus of the ongoing R&D efforts in the company's research facilities, located in India and the U.S. Products, many of which are both Kosher and Halal, are extensively researched, patented, and supported by hundreds of published clinical studies. Sabinsa's botanical cultivation program totals nearly 40,000 acres to ensure sustainable, fair-trade materials are used in these ingredients. For more information, visit [sabinsa.com](http://sabinsa.com).

#### **Media Contact**

Suzanne Shelton  
The Shelton Group  
[Suzanne@SheltonGroupPR.com](mailto:Suzanne@SheltonGroupPR.com)  
Cell: 847-922-5454